Biotechnology firms have emerged as a beacon of hope in the medical field, heralding innovative treatments and personalized medicine. However, as these companies grow, there’s a concerning trend: biotech firms increasingly adopt practices typical of Big Pharma. While this might seem like a natural progression, it carries significant downsides that could undermine the principles that make biotech companies unique.